Thomas and Peter discuss the flawed approach taken by Merck in conducting trials for Zedamib, focusing on the use of IMT as a measurement tool instead of hard outcomes. They highlight the importance of considering lipid parameters and inflammatory markers when evaluating drug efficacy.
